SC Seeks Medicine Price Caps Amid ₹8,447 Cr Overcharging Claims

The Supreme Court of India has directed the Central Government to formulate comprehensive pricing regulations across all pharmaceutical products after questioning why a 30% trade margin cap was restricted solely to anti-cancer medicines. Highlighting massive discrepancies between procurement costs and retail prices, the court emphasized the urgent need to address systemic overcharging that leaves thousands of crores in recovery claims uncollected.

What Prompted the Supreme Court's Action?

The legal scrutiny intensification stems from a Centre disclosure revealing that trade margins on critical anti-cancer drugs were capped at 30%. A Supreme Court Bench comprising Justices Vikram Nath and Sandeep Mehta strongly questioned the selective nature of this policy, asking why similar margin restrictions could not be extended to cover all essential medicines, devices, and hospital consumables. The court noted severe markups in everyday medical items—such as basic saline drip lines priced at ₹270 despite having manufacturing or procurement costs near ₹11—calling out the exploitation of patients forced to pay inflated Maximum Retail Prices (MRPs).

Why Is the Outstanding Overcharging Demand So High?

India's pharmaceutical pricing regulator faces a structural challenge in recovering dues from defaulting pharmaceutical manufacturers and distributors. Outstanding overcharging claims have ballooned to ₹8,447 crore, which accounts for roughly 84% of total cumulative demands raised over time. This unrecovered figure is more than five times the actual amount realized by enforcement authorities, exposing deep enforcement loopholes, protracted legal disputes, and delayed compliance mechanisms under the Drugs (Prices Control) Order (DPCO) framework.

How Big Is the Gap Between Supply and Retail Prices?

The gap between the price at which medicines and medical supplies are provided to retailers or hospitals and the final price billed to patients often ranges from 170% to well over 700%. In certain non-scheduled categories, markups reach exorbitant levels because manufacturers compete to offer higher trade margins to hospitals and retailers rather than offering lower prices to consumers. This incentive structure leads healthcare providers to prioritize stocking and prescribing high-margin brands, leaving consumers bearing the financial brunt of inflated MRPs.

Who Does the Current System Affect the Most?

While insured patients or those covered under government healthcare schemes benefit from pre-negotiated package rates, out-of-pocket spending patients bear the complete burden of separate MRP billing. Excessive markups force millions of households into severe financial distress or poverty each year due to catastrophic medical expenses. The asymmetry of information in healthcare prevents patients from negotiating prices or selecting cheaper generic alternatives, making strong regulatory oversight vital for public health protection.

What Steps Must the Centre Take Next?

The Supreme Court has instructed the Central Government to present workable modalities for extending trade margin caps and price regulations across the broader pharmaceutical market. Rather than limiting price intervention to a narrow list of scheduled formulations or specific disease categories like oncology, the government must strike a balance that protects consumer affordability without hampering drug availability or market viability. The apex court has set the next detailed hearing for October 27 to review the proposed regulatory framework.